Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 4Breast Neoplasms 4Melanoma 3Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Pancreatic Neoplasms 2Healthy Participants 2Advanced Solid Tumor 2cMET-dysregulated Advanced Solid Tumors 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Solid Tumor, Adult 1Solid Tumor 1Sarcoma, Synovial 1Sarcoma, Alveolar Soft Part 1Sarcoma 1Neoplastic Cells, Circulating 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Medulloblastoma 1Liver Cirrhosis 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Head and Neck Neoplasms 1Drug-drug Interaction,SHR3680 1Colorectal Neoplasms 1Advanced Solid Malignancies 1Advanced Pancreatic Cancer 1

Interventions

Irinotecan 2Injections 2vistusertib 1urelumab 1sapanisertib 1pembrolizumab 1durvalumab 1danvatirsen 1ceralasertib 1cediranib 1atezolizumab 1ZD4054 1Topotecan 1Tiragolumab 1Rosuvastatin Calcium 1Radiotherapy 1Rabeprazole 1Metformin 1HM781-36B 1Furosemide 1Digoxin 1ATP Binding Cassette Transporter, Subfamily B, Member 1 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 13-(1-benzenesulfonyl-2,3-dihydro-1H-indol-5-yl)-N-hydroxyacrylamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Solid Malignancies × Digoxin × Clear all
NCT06899061 2026-03-27

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

AstraZeneca

Phase 1 Active not recruiting
41 enrolled

Advanced Solid Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡